Researchers have discovered in a clinical trial that a new malaria vaccine called Sanaria PfSPZ-CVac has almost a 100 percent effectiveness against the disease.
A new study conducted by the team of scientists from the Wellcome Trust Sanger Institute and their national collaborators aims to extract genome sequences to fight malaria that still cause 10 million cases each year.
